|Bid||0.00 x 900|
|Ask||106.03 x 900|
|Day's range||103.91 - 105.63|
|52-week range||91.51 - 122.16|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||36.59|
|Forward dividend & yield||1.60 (1.61%)|
|Ex-dividend date||12 Aug 2022|
|1y target est||N/A|
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.
Novo Nordisk, Suncor Energy, Nasdaq, W.W. Grainger and Textron are included in this Analyst Blog.
Today's Research Daily features new research reports on 12 major stocks, including Novo Nordisk A/S (NVO), Suncor Energy Inc. (SU) and Nasdaq, Inc. (NDAQ).